New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
about
Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabPro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease.GenePANDA-a novel network-based gene prioritizing tool for complex diseasesEmerging therapeutic targets and strategies in Crohn's disease.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.
P2860
New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
New targeted therapies such as ...... of inflammatory bowel disease.
@en
type
label
New targeted therapies such as ...... of inflammatory bowel disease.
@en
prefLabel
New targeted therapies such as ...... of inflammatory bowel disease.
@en
P2093
P2860
P1476
New targeted therapies such as ...... of inflammatory bowel disease.
@en
P2093
Ivana Bravatà
Mariangela Allocca
Silvio Danese
P2860
P304
P356
10.3109/00365521.2014.993700
P577
2015-01-01T00:00:00Z